Phase I/II trial of epratuzumab (humanized anti-CD22 antibody) in indolent non-Hodgkin's lymphoma

Journal of Clinical Oncology

Volumn 21, Issue 16, 2003, Pages 3051-3059

  Leonard, John P ^a   Coleman, Morton ^a   Ketas, Jamie C ^a   Chadburn, Amy ^a   Ely, Scott ^a   Furman, Richard R ^a   Wegener, William A ^a   Hansen, Hans J ^a   Ziccardi, Heather ^a   Eschenberg, Michael ^a   Gayko, Urte ^a   Cesano, Alessandra ^a   Goldenberg, David M ^a  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BLEOMYCIN; CARMUSTINE; CISPLATIN; CLADRIBINE; CYCLOPHOSPHAMIDE; CYTARABINE; DEXAMETHASONE; DOXORUBICIN; EPRATUZUMAB; ETOPOSIDE; FLUDARABINE; IFOSFAMIDE; MESNA; METHYLPREDNISOLONE; MITOXANTRONE; PREDNISONE; RITUXIMAB; THIOTEPA; TOSITUMOMAB I 131; VINCRISTINE; ANTINEOPLASTIC AGENT; B LYMPHOCYTE ANTIGEN; CD22 ANTIGEN; CD22 PROTEIN, HUMAN; CELL ADHESION MOLECULE; HLL2 AGENT; LECTIN; LEUKOCYTE ANTIGEN; MONOCLONAL ANTIBODY;

ABSENCE OF SIDE EFFECTS; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; B LYMPHOCYTE; CANCER RADIOTHERAPY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG DOSE ESCALATION; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG HALF LIFE; DRUG SAFETY; FOLLICULAR LYMPHOMA; HUMAN; MAJOR CLINICAL STUDY; NONHODGKIN LYMPHOMA; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; T LYMPHOCYTE; UNSPECIFIED SIDE EFFECT; WHOLE BODY RADIATION; ADULT; DRUG EFFECT; FEMALE; HALF LIFE TIME; IMMUNOLOGY; LYMPHOCYTE; MALE; MIDDLE AGED;

ADULT; ANTIBODIES, MONOCLONAL; ANTIGENS, CD; ANTIGENS, CD22; ANTIGENS, DIFFERENTIATION, B-LYMPHOCYTE; ANTINEOPLASTIC AGENTS; CELL ADHESION MOLECULES; FEMALE; HALF-LIFE; HUMANS; LECTINS; LYMPHOCYTES; LYMPHOMA, NON-HODGKIN; MALE; MIDDLE AGED;

EID: 0042413843     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2003.01.082     Document Type: Article

References (31)

1. Young RC, Longo DL, Glatstein E, et al: The treatment of indolent lymphomas: Watchful waiting v aggressive combined modality treatment. Semin Hematol 25:11-16, 1988 (suppl 2)
2. Multani P, White CA, Grillo-Lopez A: Non-Hodgkin's lymphoma: Review of conventional treatments. Curr Pharm Biotechnol 2:279-291, 2001
3. Apostolidis J, Foran JM, Johnson PW, et al: Patterns of outcome following recurrence after myeloablative therapy with autologous bone marrow transplantation for follicular lymphoma. J Clin Oncol 17:216-221, 1999
4. Solal-Celigny P, Lepage E, Brousse N, et al: Doxorubicin-containing regimen with or without interferon alfa-2b for advanced follicular lymphomas: Final analysis of survival and toxicity in the Groupe d'Etude des Lymphomes Folliculaires 86 Trial. J Clin Oncol 16:2332-2338, 1998
5. Maloney D, Grillo-Lopez AJ, Bodkin DJ, et al: IDEC-C2B8: Results of a phase I multiple-dose trial in patients with relapsed non-Hodgkin's lymphoma. J Clin Oncol 15:3266-3274, 1997
6. Maloney D, Grillo-Lopez A, White C, et al: IDEC-C2B8 (rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma. Blood 90:2188-2195, 1997
7. McLaughlin P, Grillo-Lopez AJ, Link BK, et al: Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: Half of patients respond to a four-dose treatment program. J Clin Oncol 16:2825-2833, 1998
8. Piro LD, White CA, Grillo-Lopez AJ, et al: Extended rituximab (anti-CD20 monoclonal antibody) therapy for relapsed or refractory low-grade or follicular non-Hodgkin's lymphoma. Ann Oncol 10:655-661, 1999
9. Dorken B, Moldenhauer G, Pezzutto A, et al: HD39 (B3), a B lineage-restricted antigen whose cell surface expression is limited to resting and activated human B lymphocytes. J Immunol 136:4470-4479, 1986
10. Vittetta ES, Stone M, Amlot P, et al: Phase I immunotoxin trial in patients with B-cell lymphoma. Cancer Res 51:4052-4058, 1991
11. Sato S, Tuscano JM, Inaoki M, et al: CD22 negatively and positively regulates signal transduction through the B lymphocyte antigen receptor. Semin Immunol 10:287-297, 1998
12. Engel P, Nojima Y, Rothstein D, et al: The same epitope on CD22 of B lymphocytes mediates the adhesion of erythrocytes, T and B lymphocytes, neutrophils, and monocytes. J Immunol 150:4719-4732, 1993
13. Otipoby KL, Andersson KB, Draves KE, et al: CD22 regulates thymus-independent responses and the lifespan of B cells. Nature 384:634-637, 1996
14. Sato S, Miller AS, Inaoki M, et al: CD22 is both a positive and negative regulator of B lymphocyte antigen receptor signal transduction: Altered signaling in CD22-deficient mice. Immunity 5:551-562, 1996
15. Leung SO, Goldenberg DM, Dion AS, et al: Construction and characterization of a humanized, internalizing, B-cell (CD22)-specific, leukemia/lymphoma antibody, LL2. Mol Immunol 32:1413-1427, 1995
16. Pawlak-Byczkowska EJ, Hansen HJ, Dion AS, et al: Two new monoclonal antibodies, EPB-1 and EPB-2, reactive with human lymphoma. Cancer Res 49:4568-4577, 1989
17. Stein R, Belisle E, Hansen HJ, et al: Epitope specificity of the anti-(B cell lymphoma) monoclonal antibody, LL2. Cancer Immunol Immunother 37:293-298, 1993
18. Oken MM, Creech RH, Tormey DC, et al: Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 5:649-655, 1982
19. Lefranc MP, Lefranc G: The Immunoglobulin Facts Book. San Diego, CA, Academic Press, 2001, pp 22-23
20. Cheson BD, Horning SJ, Coiffier B, et al: Report of an International Workshop to Standardize Response Criteria for Non-Hodgkin's Lymphomas. J Clin Oncol 17:1244-1253, 1999
21. Spinolo JA, Cabanillas F, Dixon DO, et al: Therapy of relapsed or refractory low-grade follicular lymphomas: Factors associated with complete remission, survival and time to treatment failure. Ann Oncol 3:227-232, 1992
22. Wiseman GA, White CA, Witzig TE, et al: Radioimmunotherapy of relapsed non-Hodgkin's lymphoma with Zevalin, a 90Y-labeled anti-CD20 monoclonal antibody. Clin Cancer Res 5:3281s-3286s, 1999 (suppl 10)
23. Knox SJ, Goris ML, Trisler K, et al: Yttrium-90-labeled anti-CD20 monoclonal antibody therapy of recurrent B-cell lymphoma. Clin Cancer Res 2:457-470, 1996
24. Juweid M, Sharkey RM, Markowitz A, et al: Treatment of non-Hodgkin's lymphoma with radiolabeled murine, chimeric, or humanized LL2, and anti-CD22 monoclonal antibody. Cancer Res 55:5899s-5907s, 1995 (suppl 1)
25. Tuscano JM, Riva A, Toscano SN, et al: CD22 cross-linking generates B-cell antigen receptor-independent signals that activate the JNK/SAPK signaling cascade. Blood 94:1382-1392, 1999
26. Uppenkamp M, Engert A, Diehl V, et al: Monoclonal antibody therapy with CAMPATH-1H in patients with relapsed high- and low-grade non-Hodgkin's lymphomas: A multicenter phase I/II study. Ann Hematol 81:26-32, 2002
27. Khorana A, Bunn P, McLaughlin P, et al: A phase II multicenter study of CAMPATH-1H antibody in previously treated patients with nonbulky non-Hodgkin's lymphoma. Leuk Lymphoma 41:77-87, 2001
28. Coiffier B, Lepage E, Briere J, et al: CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 346:235-242, 2002
29. Hernandez-Ilizaliturri F, Gada P, Repasky E, et al: Enhancement in anti-tumor activity of rituximab when combined with epratuzumab or apolizumab (Hu1D10) in a B-cell lymphoma severe combined immunodeficiency (SCID) mouse model. Blood 100:591, 2002 (abstr)
30. Leonard JP, Coleman M, Matthews JC, et al: Combination monoclonal antibody therapy for lymphoma: Treatment with epratuzumab (anti-CD22) and rituximab (anti-CD20) is well tolerated. Blood 98:344, 2001 (abstr)
31. Leonard JP, Coleman M, Matthews JC, et al: Epratuzumab (anti-CD22) and rituximab (anti-CD20) combination immunotherapy for non-Hodgkin's lymphoma: Preliminary response data. Proc Am Soc Clin Oncol 21:1060, 2002 (abstr)